EndoSe from Streptococcus equi subsp. equi is an enzyme hydrolyzing glycosyl groups on IgG, analogous to EndoS from Streptococcus pyogenes. We here show that the activity of EndoSe leads to an antiphagocytic function and may thus be a contributory factor to immune evasion of S. equi. Despite the damaging effect that EndoSe has on IgG, antibodies against EndoSe can neutralize its function. Antibodies against EndoSe restored the opsonic activity of specific opsonizing antibodies. Mice infected with either S. equi subsp. equi or subsp. zooepidemicus or S. pyogenes could be protected by vaccination with EndoSe. It is speculated that EndoSe could be a suitable vaccine candidate against streptococcal infections.
E
ndoS is a glycosyl hydrolase from Streptococcus pyogenes, which can hydrolyze the glycan on the IgG Fc region (4, 5, 7) . For IgG, there is a conserved asparagine residue (position 297 in human IgG), which is known to be linked to glucans in different species. The N-linked sugars that are attached to IgG have a common biantenna core structure, consisting of two N-acetylglucosamines (GlcNAc) and three mannoses. The Fc region is recognized by Fc receptors on phagocytic cells and is also required for complement activation. The intactness of the Fc region is required for recognition (16) , and the hydrolysis by EndoS of the glycan group is part of a bacterial system evading the adaptive immune system. This was demonstrated by the enhanced survival of S. pyogenes in blood in the presence of EndoS, which neutralized opsonic IgG (7) . It has also been demonstrated that complementmediated hemolysis caused by antibodies against red blood cells was inhibited by EndoS (2) .
The damaging effect of EndoS on IgG has led to the speculation, supported by experimental findings, that EndoS could be used as a treatment against autoimmune disorders caused by antibodies (1, 3, 6, 22) .
Streptococcus equi subsp. equi is the causative agent of strangles in horses (12, 19) . This is a highly contagious infection and the most costly bacterial infection in the horse. A single outbreak often leads to consequences such as closure of a stable or riding school. S. equi subsp. equi adheres to the tonsils and spreads via the lymphatic system, leading to lymph node abscesses, which can rupture through the skin, into the guttural pouches, and into the nasal cavities. A purulent nasal discharge and swollen lymph nodes are therefore typical signs of strangles, along with pyrexia. There is thus a high demand for a safe and efficient vaccine against S. equi subsp. equi infections, and steps toward such a vaccine have been taken (9) .
The genome of S. equi subsp. equi has approximately 80% sequence identity with S. pyogenes (13) , and the mode of infection resembles tonsillitis caused by S. pyogenes (20) . S. equi subsp. equi seems to have been evolved by lateral transfer of genes from S. pyogenes into S. equi subsp. zooepidemicus (13) . EndoSe, a protein from S. equi subsp. equi with a striking homology with EndoS from S. pyogenes, has thus been identified and characterized here.
MATERIALS AND METHODS

Growth of bacteria.
Streptococcus equi subsp. equi 1866 (SeM type 9), Streptococcus equi subsp. zooepidemicus (strain 1577, ST8), and Streptococcus pyogenes (strain MGAS 5005) were grown overnight at 37°C in 5% CO 2 in Todd-Hewitt broth supplemented with 1% yeast extract (THY). The culture was diluted 10 times into 50 ml of fresh THY with 10% horse serum (Sigma) and grown for 4 more hours without shaking. All bacteria were passaged through mice before use. This was done by isolating a single colony recovered after 3 days from the nostrils of a mice infected with approximately 10 7 CFU. The passaged isolate was grown on a blood agar plate for one cycle only and then kept at Ϫ70°C. Escherichia coli carrying recombinant plasmids was grown in LB supplemented with ampicillin (50 g/ml).
Cloning of the gene for EndoSe. Chromosomal DNA from S. equi subsp. equi strain 1866 was used to amplify the endoSe gene, or fragments of it, using the following primers: forward, 5=-GTCGGATCCGAGGATA-AGGTTGTGCAAACTAG; and reverse, 5=-GCCTCTCGAGGGATAAGC TAGTCTGTCTTTGG) (restriction enzyme cleavage sites in bold). The cloned gene is identical to the published sequence for strain 4047 (13) except for one nucleotide change leading to an amino acid change from N to Y in position 315. The N-terminal part (encoding EndoA, amino acids 1 to 260) was amplified with the same forward primer and reverse primer 5=-GCAGCTCGAGTTAATATTGGGCACCGCGCTCAATC. For the Cterminal part (encoding EndoC, amino acids 802 to 982), the same reverse primer was used as for EndoA in combination with forward primer 5=-T GACGGATCCAAGGAGGCCAAGCTTGAAGC. Cleavage sites for the restriction enzymes BamHI and XhoI (in bold) were included in the primer sequences to match the cloning sites in the plasmid vector pGEX-6P-1 (GE Healthcare). The PCR amplifications were performed using the primers (20 pmol/l) and FideliTaq PCR master mix (USB Corporation, Cleveland, OH): step 1, preheating for 1 min at 95°C; step 2, 30 s at 95°C; step 3, annealing for 15 s at 5°C below the respective primer combination melting point; and step 4, elongation for 2 min at 72°C. Steps 2 to 4 were run for 30 cycles. The PCR products were purified from 1% agarose gels using the QIAquick PCR purification kit (Qiagen). After restriction cleavage, the fragments were purified once more. The fragments were ligated into the plasmid using ReadyToGo T4 DNA ligase (GE Healthcare) followed by transformation into E. coli TG1 with electroporation and selection on LA-Amp plates (Luria-Bertani broth agar [15 g/liter] plates with ampicillin; final concentration, 50 g/ml). The presence of an insert in the constructs was verified by PCR using appropriate primer combinations, and sequences of the inserts were determined. Correct clones were transformed into E. coli strain BL21(DE3) pLys for protein expression.
The cloning and expression of IdeE and IdeE2 are described in reference 14. However, in this work, the IdeE2 gene was recloned into the pGex6p-1 vector, resulting in expression of full-length IdeE2. The purification of IdeE and IdeE2 was done as described for EndoSe.
Purification of full-length EndoSe and parts of EndoSe. Purification of recombinant proteins was done according to the manufacturer's instructions. Briefly, clones encoding full-length EndoSe, fragment A (Nterminal portion), and fragment C (C-terminal portion) of EndoSe were grown at 37°C in LB broth with ampicillin (50 g/ml). At an optical density at 600 nm (OD 600 ) of ϳ0.6, IPTG (isopropyl-␤-D-thiogalactopyranoside) was added to a final concentration of 0.2 mM, and the growth temperature was shifted to 15°C. After incubation overnight, the E. coli cells were harvested and resuspended in phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 [pH 7.4]) supplemented with Tween 20, final concentration 0.1% (vol/vol) (PBST), and lysozyme was added to 50 g/ml, whereupon the cells were lysed by freezing and thawing. After centrifugation, the supernatant was sterile filtered and batch purified with glutathione-Sepharose beads. After extensive washing using PBST, the fusion protein was treated with scissor protease to release the recombinant proteins. The eluted samples containing the antigens were dialyzed against PBS and quantified by spectrophotometry, and the quality was analyzed by SDS-PAGE. Each protein produced in this system contains an additional Gly-Pro-Leu-Gly-Ser derived from the vector.
Treatment of IgG or sera with EndoSe. Horse IgG (Bethyl), human IgG (Bethyl), and mouse IgG (Sigma) at concentrations of 1 mg/ml were treated with EndoSe and the IgG was separated on SDS-PAGE and blotted onto Hybond-C extra filter. The treatment of IgG was done by incubation of 18 l of IgG (1 mg/ml) with 2 l of EndoSe (0.6 mg/ml) at 37°C for 1 h. To assay the hydrolyzing activity of EndoSe on IgG in sera, the sera were diluted 4 times in PBS and 2 l was mixed with 7 l PBS and incubated with 1 l EndoSe (0.6 mg/ml) for 1 h at 37°C. To assay inhibitory activity of mouse immune sera (pooled from four mice immunized with EndoSe), human IgG was first cleaved with a combination of IdeE and IdeE2. The cleavage of human IgG was done by mixing 180 l of IgG (1 mg/ml) with 3 l of IdeE (1.5 mg/ml), 9 l of IdeE2 (0.5 mg/ml), and 2 l of dithiothreitol (DTT) (0.1 M), and the mixture was incubated at 37°C for 1 h. Two microliters of diluted mouse immune sera was mixed with 2 l of EndoSe (12.5 g/ml) for 10 min at room temperature, and thereafter 6 l of the cleaved human IgG was added and the mixture was incubated for 1 h at 37°C.
SDS-PAGE and Western blotting. SDS-PAGE was run under reducing conditions using the Phast system (8 to 25% gel [GE Health Care, Uppsala, Sweden]), the separated proteins were blotted onto Hybond-C extra (Amersham Biosciences), and the filters were blocked for 30 min in PBST. The blocked filters were incubated with Lens culinaris agglutinin (LCA) labeled with biotin (Immunkemi, Järfälla, Sweden) diluted 500 times in PBST for 1 h. The filters were then washed (PBST) and treated with peroxidase-labeled streptavidin (Immunkemi) diluted 500 times in PBST for 30 min. After washing, the filters were assayed for peroxidase activity using 4-chloro-1-naphtol as a substrate.
Culturing human monocyte line THP-1. A cell line of human monocytes, THP-1 (ATCC TIB-202) was cultured in 25-cm 2 flasks with 5 ml of culture medium consisting of 90% RPMI 1640 (Sigma) and 10% fetal bovine serum supplemented with 2 mM L-glutamine (Gibco Invitrogen), 20 mM HEPES, and antibiotics (gentamicin [5 g/ml], penicillin [100 IU/ml], and streptomycin [100 g/ml]). Fresh culture medium was supplied 3 or 4 times a week. The cells were kept at a concentration of 5 ϫ 10 5 to 1 ϫ 10 6 cells/ml in a cell culture incubator at 37°C and 5% CO 2 . Fresh cells at a concentration of 7 ϫ 10 5 to 1.3 ϫ 10 6 cells/ml were activated for 48 h by the addition of phorbol 12-myristate-13-acetate (PMA) (Sigma) to a final concentration of 10 Ϫ8 M. For opsonization studies with Staphylococcus epidermidis, the cells were seeded onto a 48-well cell culture plate without the addition of antibiotics (250 l/well, resulting in 1.75 ϫ 10 5 to 3.25 ϫ 10 5 cells/well). For flow cytometry, cells were maintained in flasks. Transformation was confirmed by morphological examination under a microscope.
Phagocytocis of S. epidermidis 269 opsonized with antibodies against Fbe. S. epidermidis 269 was grown in LB for 3 h, washed, and resuspended in RPMI to 1 ϫ 10 5 CFU/ml. Five hundred microliters of bacteria was opsonized for 60 min at 37°C in 15-fold-diluted sheep serum directed against fibrinogen-binding protein (Fbe) (17) or extracellular adherence protein (Eap) (10) . The sheep sera were pretreated with EndoSe at 0, 4, 30, or 200 g/ml for 40 min at 37°C. One hundred microliters of opsonized bacteria was then added to wells with activated THP-1 cells to give a multiplicity of infection (MOI) of 0.1. The plate was then placed at 37°C with 5% CO 2 . After 90 min, the wells were washed gently 2 times with cell growth medium before cell growth medium supplemented with 25 l/ml lysostaphin (Sigma) was added. This effectively kills free bacteria remaining after washing, while bacteria phagocytosed by macrophages remain intact. The plates were further incubated with lysostaphin (Sigma) for 20 min in 37°C with 5% CO 2 . The wells were then washed gently again 2 times with cell growth medium, and then 250 l of sterile water was added, lysing the macrophages. Internalized bacteria released from macrophages were enumerated on LB agar plates. Ingested bacteria/macrophage was calculated.
Flow cytometry. PMA-activated THP-1 cells were detached from the flasks by gently shaking the flasks for 10 min with 1 mM EDTA at 37°C. The cells were centrifuged for 5 min at 700 rpm and then resuspended to 10 6 cells/ml in fluorescence-activated cell sorter (FACS) buffer (PBS with 1 mg/ml bovine serum albumin and 2 mM NaN 3 ). Human IgG (at 30 g/ml) was pretreated with various concentrations of EndoSe (0 to 320 g/ml) for 20 min at 20°C. The EndoSe-treated IgG was then added at a final concentration of 0.15 g/ml to 10 5 THP-1 cells, which were further incubated for 15 min at 20°C. The cells were centrifuged for 5 min at 300 rpm and resuspended in 400 l FACS buffer to which 4 l of fluorescein isothiocyanate (FITC)-conjugated rabbit Fab fragment against human IgG (DakoCytomation, Glostrup, Denmark) was added. Lacking the Fc portion, these antibodies cannot bind to the cells directly; binding has to be mediated by an intact human IgG molecule. The cells were incubated for 15 min at 20°C, centrifuged, and resuspended in FACS buffer. In separate experiments, EndoSe at 320 g/ml was also mixed with various amounts (0 to 50%) of anti-EndoSe serum and incubated for 10 min at 20°C before it was added (at 180 g/ml) to the human IgG as described. To generate anti-EndoSe serum, mice were immunized with EndoSe on three occasions with 10 g each time, using Abisco 300 as the adjuvant (Isconova, Uppsala, Sweden). Preimmune serum was used as the negative control. In pilot experiments, it was demonstrated that the addition of mouse serum did not interfere with the detection of human IgG binding to the cells (data not shown).
The cells were collected using a FACSAria flow cytometer (BD Biosciences), and the percentage of cells positive for IgG binding was calculated using FlowJo software (version 8.8.6, Tree Star).
Binding of IgG to immobilized EndoSe. EndoSe (at 70 g/ml) was incubated for 30 min at 37°C in various concentrations (0.3 to 40%) of anti-EndoSe serum or preimmune control serum. Such serum-treated EndoSe was added (resulting in a final concentration of 12 g/ml) to horse IgG (at 1 mg/ml) (Jackson ImmunoResearch Laboratories). The IgG was treated at 37°C for 2 h. One hundred microliters of the EndoSetreated IgG was then, after 50-fold dilution in PBST (resulting in a final concentration of 20 g/ml), added to microtiter wells (Nunc) to which EndoSe had been coated at 10 g/ml. Prior to the addition of IgG, free sites were blocked by adding 2% bovine serum albumin (BSA) for 1 h at 37°C. Binding of IgG was determined with horseradish peroxidase (HRP)-conjugated anti-horse IgG (Sigma) followed by development with OPD substrate (Dako). In pilot experiments, optimal concentrations of antiserum-treated EndoSe and of IgG were determined, as was the optimal coating concentration of EndoSe.
Mouse model of infection and vaccination. The procedure described before (8, 9) was used. Briefly female NMRI mice (25 to 28 g) were vaccinated intranasally at three occasions with 12 g antigen mixed with 10 g Abisco 300 (Isconova, Uppsala, Sweden) on days 0, 14, and 21. For all experiments, a control group was included, in which mice were given placebo vaccine containing adjuvant only. All mice responded well as determined in an enzyme-linked immunosorbent assay (ELISA) described earlier (9) (data not shown). On day 28, bacteria were applied to both nostrils. In pilot experiments, the optimal bacterial dose to cause colonization was determined; for S. equi subsp. equi 10 6 CFU, for S. equi subsp. zooepidemicus 9 ϫ 10 6 CFU, and for S. pyogenes 8 ϫ 10 7 CFU in a volume of 10 l. The mice were followed daily for weight loss and nasal colonization, measured as shedding of bacteria from the nostrils. For determination of nasal colonization, blood agar plates containing gentian violet, to select for streptococcal growth, were very gently touched onto the nostrils 10 times. Bacteria were spread out on the plates, which were then incubated overnight in a 5% CO 2 enriched atmosphere. Due to the mucoid nature of S. equi subsp. equi colonies, a semiquantitative scoring system was used, where four categories (0 to 3) of growth could easily be distinguished: 0 to 5 colonies was scored as 0, 5 to 100 colonies as 1, Ͼ100 colonies as 2, and confluent growth as 3. This noninvasive procedure enumerates only bacteria residing in the nostrils, but colonization in the entire nasopharynx region has been demonstrated. Animal experimentation was approved by the regional ethical committee.
Statistical analysis. Student's t test was used for all comparisons between groups, except for comparison of bacterial shedding of infected mice. Here, a low level of shedding, scoring 0 to 1.5, was compared to a high level of colonization, i.e., a score of 2 to 3, using Fisher's exact test.
RESULTS
EndoSe identification.
Based on sequence homology with EndoS from S. pyogenes, a similar gene was identified in the genome sequence of S. equi subsp. equi strain 4047 (Sanger database), and the gene was cloned from S. equi subsp. equi strain 1866. The gene encodes a predicted signal peptide and was cloned in three different parts, the N-terminal part (EndoN), the C-terminal part (EndoC), and the predicted mature protein EndoSe. The mature protein consists of 982 amino acids and is predicted to be secreted based on the homology to EndoS (7) and the lack of cell wall anchoring motifs. Like EndoS, it has glycosyl hydrolase family 18 motif located in the N-terminal part. EndoSe has approximately 70% identity to EndoS from S. pyogenes strains (12 unique versions of EndoS identified by NCBI protein blast). A gene encoding Endo is also found in three publicly available genome sequences from S. equi subsp. zooepidemicus strains (EndoSz), and they show an amino acid identity of 86 to 88% with EndoSe. These different versions of Endo are of similar size and the homology is fairly evenly distributed over the entire protein, although the C-terminal part is more divergent. EndoSe/EndoSz contains an additional 30 amino acids in the end. Interestingly, an integrin binding motif, RGD, is found in EndoSe from S. equi subsp. equi and S. equi subsp. zooepidemicus but not in EndoS from S. pyogenes strains. In the corresponding position in 12 unique EndoS versions from different S. pyogenes strains, the motif is instead KGD.
EndoSe has a hydrolytic function on IgG glycosylation. Human, equine, and murine IgGs were run on SDS-PAGE, with or without prior treatment with EndoSe, followed by a Western blot analysis probed with Lens culinaris agglutinin (LCA) lectin. LCA recognizes ␣-linked mannose residues in the conserved complex carbohydrate structure attached to the asparagine 297 residue in the CH2 domain of human IgG. The asparagines are conserved also in horse and mouse IgGs. This binding was impaired by EndoSe treatment, as shown in Fig. 1A and B. Human IgG was also specifically proteolytically cleaved with IdeE (15) and IdeE2 (14) to reduce the size of IgG and to improve resolution on SDS-PAGE. Figure 2A , lane 1, shows the cleaved IgG, and in lane 2 the effect of EndoSe treatment on the cleaved IgG is shown, a clear shift in the mobility of the IgG. Pretreatment of EndoSe with a control mouse serum has no effect of the hydrolyzing ability on IgG (lane 3). However, serum from a mouse immunized with EndoSe could block the hydrolyzing effect of EndoSe, even at a 128-fold dilution (lanes 4 to 7). Figure 2B shows a Western blot of Fig. 2A probed with LCA, demonstrating the hydrolyzing effect that EndoSe has on IgG and that antibodies directed against EndoSe efficiently can inhibit the enzymatic activity of EndoSe. The reason for using human IgG is that it can be completely cleaved by the use of the IgG-specific endopeptidases IdeE and IdeE2. If the IgG is not precleaved, the effect of EndoSe hydrolyzation would be masked by the mouse antibodies used for the inhibition. Horse IgG contains 7 different subtypes, of which all are not equally well cleaved by the endopeptidases used. In addition to the added cleaved IgG in Fig.  2 , extra protein bands can also be observed. These proteins come from the added serum ( Fig. 2A, lanes 3 to 7) , and the major 66-kDa protein corresponds to albumin. In Fig. 2B , lanes 4 and 5, an approximately 50-kDa protein is detected with the LCA probe, which fits well with the size of the heavy chain of IgG. This protein is not detected in lane 3 due to the effect of uninhibited EndoSe in the presence of the control serum.
EndoSe blocks the function of opsonic antibodies. To determine the ability of EndoSe to damage the opsonic function of antibodies, two separate systems were used to demonstrate the effect of EndoSe: (i) antibody-stimulated phagocytosis of Staphylococcus epidermidis, and (ii) determination of IgG binding to macrophages using flow cytometry.
The system used is one in which antibodies have previously been demonstrated to have opsonic function in vitro and which could be quantified better than opsonization of S. equi subsp. equi. Antibodies against a surface-located fibrinogen-binding protein on Staphylococcus epidermidis (Fbe/SdrG) have been shown to opsonize and stimulate uptake of Staphylococcus epidermidis into macrophages (18, 21) . As a negative control, antibodies against extracellular adherence protein (Eap) (11) from Staphylococcus aureus, which cannot opsonize Staphylococcus epidermidis (data not shown), were used. Sheep sera against Fbe/SdrG or Eap were therefore treated with various concentrations of EndoSe. Figure 3 shows that the opsonic function of anti-Fbe/SdrG antibodies was significantly reduced by EndoSe treatment to a background level, similar to mock opsonization with anti-Eap antibodies.
Next, various amounts of EndoSe were added to human IgG before addition to the human macrophage cell line THP-1, and the binding of IgG was quantified using flow cytometry. Figure 4A shows that a dose-dependent decrease in binding of IgG to macrophages resulted when increasing EndoSe concentrations were added.
EndoSe was also treated with antiserum against EndoSe before it was added to IgG, which was then subsequently added to macrophages. The inhibitory effect that EndoSe has on IgG binding to macrophages, analyzed by flow cytometry and shown in Fig. 4A , was now eliminated, as shown in Fig. 4B . Binding of IgG to macrophages was restored by the addition of anti-EndoSe serum to EndoSe, which thereby became neutralized in a dose-dependent way. Negative serum did not have any effect on EndoSe.
Binding of EndoSe to IgG. Due to the catalytic function of EndoSe on IgG, equine IgG could bind in a dose-dependent way to immobilized EndoSe in microtiter wells. However, if IgG was pretreated with a 50:1 stoichiometric amount of soluble EndoSe prior to addition to the stationary-phase EndoSe, binding was completely eliminated (data not shown). In the next step, the soluble EndoSe was pretreated with various amounts of antiserum against EndoSe. The ability of EndoSe to damage the binding ability of IgG to stationary-phase EndoSe was then significantly inhibited (P ϭ 0.005 and 0.003 for 40% and 8% sera, respectively), as shown in Fig. 5 .
Protection against streptococcal infections after vaccination with EndoSe. Figure 6 shows the result from vaccination of mice with EndoSe. Mice were vaccinated with EndoSe or only adjuvant as the negative control. The mice were infected intranasally with either S. equi subsp. equi, S. equi subsp. zooepidemicus, or S. pyogenes, and weight loss and nasal colonizations measured as shedding of bacteria were followed. In the case of S. equi subsp. equiinfected mice, the group vaccinated with EndoSe was significantly protected from infection; none of these mice lost any weight (P ϭ 0.0001 for all days, compared with control group), and the bacterial shedding was minimal (P Ͻ 0.005 for all days, compared with control group). Two groups were immunized with the N-terminal portion or the C-terminal portion of EndoSe, respectively. Also, these mice were significantly protected, but not to the same level as for immunization with full-length EndoSe.
Mice challenged with S. equi subsp. zooepidemicus became infected, but to a milder extent than those infected with S. equi subsp. equi, and all mice recovered from infection from day 3 onwards. Bacterial shedding was transient and weight loss reversible. However, the group vaccinated with EndoSe was even less affected and never lost weight (P Ͻ 0.0001 for days 2 to 5). Bacterial shedding was minimal (P Ͻ 0.0002 for days 2 and 3) compared to that of the control group.
Intranasal infection with S. pyogenes resulted in a slower progress of infection. The mice vaccinated with EndoSe did not differ significantly in terms of weight loss from the nonvaccinated group. However, bacterial shedding was significantly lower in the vaccinated group (P ϭ 0.006, 0.002, 0.005, 0.002, and 0.008 for days 1 to 5, respectively). The bacterial shedding in the nonvaccinated group did not seem to lead to illness resulting in weight loss.
DISCUSSION
Based on sequence homology with EndoS from S. pyogenes, protein EndoSe from S. equi subsp. equi was identified; it has approximately 70% identity with several EndoS sequences from strains of S. pyogenes. A similar protein also exists in S. equi subsp. zooepidemicus, with 86% identity. The findings reported here imply a functional similarity between EndoSe from S. equi subsp. equi and EndoS from S. pyogenes, with hydrolysis of sugar substituents of glycosylated IgG thereby impairing the antibacterial effect of IgG. This function of EndoSe has here been determined by a combination of experimental approaches: (i) as removal of sugars on IgG recognized by LCA in Western blotting, (ii) inhibition of IgG binding to Fc receptors on macrophages shown in flow cytometry, (iii) inhibition of opsonic function of IgG, and (iv) by demonstration of direct binding between EndoSe and IgG. Cumulatively, these data suggest that, like EndoS from S. pyogenes (7), EndoSe participates in evasion of the host immune system.
Due to the IgG-damaging effect of EndoSe, one could hypothesize that IgG specifically directed against EndoSe might not be very efficient in its ability to neutralize EndoSe. However, we have here demonstrated that antibodies against EndoSe have the capacity to neutralize all the functions demonstrated for EndoSe and also to inhibit the direct binding of IgG to EndoSe. Clearly the N-linked oligosaccharide on IgG is not required for IgG against EndoSe to be neutralizing.
Furthermore, vaccination with EndoSe resulted in significant protection against S. equi subsp. equi infection as compared with placebo controls containing adjuvant only. An enhanced innate immunity cannot account for the protection, based on the highly significant difference between vaccine and control groups. Three different portions of EndoSe were used; full length, the N terminus, and the C terminus. The best effect was found when using 
FIG 6
Protection of mice infected with streptococci after vaccination with EndoSe. Mice were vaccinated with EndoSe (circles) (n ϭ 8 for S. equi subsp. equi challenge and n ϭ 15 for S. equi subsp. zooepidemicus and S. pyogenes and equal numbers for controls), EndoA (squares) (n ϭ 10), EndoC (triangles) (n ϭ 10), or adjuvant alone (diamonds) and infected with indicated species of streptococci. Bacterial nasal shedding (quantification as described in Materials and Methods) and weight loss were followed daily. Mean values and standard errors are shown. Significant differences between vaccinated and nonvaccinated mice (n ϭ 10 for each group) were found in bacterial shedding for all species (P ϭ 0.0002 for S. equi subsp. equi and S. equi subsp. zooepidemicus and P ϭ 0.005 for S. pyogenes). Significant differences between vaccinated and nonvaccinated mice were found for weight loss for S. equi subsp. equi and S. equi subsp. zooepidemicus (P ϭ 0.0001) but not for S. pyogenes.
full-length EndoSe and less pronounced by using only the C-terminal or the N-terminal portion of EndoSe. The full-length EndoSe thus appears to be required to yield efficient protective antibodies. As we have reported before (9), mice have been immunized with a large number of antigens derived from S. equi subsp. equi, both surface localized and secreted, resulting in various levels of protection against S. equi subsp. equi infection. Some antigens resulted in good immune response but no protection. However, the best protection was obtained by EndoSe vaccination reported here. Presumably, the neutralizing effect of antibodies against EndoSe, here demonstrated in vitro at a dilution of 1:128, also takes place in vivo where the antibodies are nondiluted.
The biological function of EndoSe appears to be to contribute to evasion of the immune system, and protective antibodies against S. equi subsp. equi will lose their opsonic function due to the presence of EndoSe, thereby reducing the efficacy of natural protective immunity or vaccination. The rationale for including EndoSe as a vaccine component is therefore to generate antibodies neutralizing the function of EndoSe. Neutralization of EndoSe would thus have an effect only in the presence of such opsonizing antibodies. However, we have here found that vaccination with EndoSe alone, without any other antigens, conferred a significant protection. This might imply that EndoSe has an additional effect on virulence, not related to its effect on IgG, also neutralized by antibodies against it. A second possibility is that the opsonic effect of IgG, also in nonimmunized mice, has a "background level" of protective effect against infection, which is eliminated by EndoSe.
In conclusion, EndoSe contributes to evasion of immune protection by IgG against S. equi subsp. equi infection. Antibodies against EndoSe can neutralize its function and are protective. We thus suggest that EndoSe can serve as a suitable vaccine candidate against S. equi subsp. equi infection in the horse; we have shown (9) that a vaccine based on recombinant proteins is a feasible task, and the amounts required can be reached by up-scaling. The similarity between the homologous proteins in S. equi subsp. zooepidemicus (EndoSz) and S. pyogenes (EndoS) implies that these corresponding proteins should also be tested as vaccine candidates against infections caused by these species.
